JONATHAN A ROSENBERG
- Type
- Physician · Allopathic & Osteopathic Physicians / Internal Medicine / Gastroenterology
- Where
- GURNEE, IL
- NPI
- 1811150725
- Received
- $1,021,440 in 1,958 records, 2019 to 2025 ($1,019,412 general, $2,028 research); ownership interests with $993 invested
- As principal investigator
- $2,105,045 of research payments to others in 532 records
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2025 | General payment | 315 | $140,200 |
| 2025 | Research payment | 1 | $96 |
| 2024 | General payment | 449 | $242,690 |
| 2024 | Ownership or investment interest | 1 | $0 |
| 2023 | General payment | 377 | $213,246 |
| 2023 | Ownership or investment interest | 1 | $0 |
| 2022 | General payment | 230 | $120,586 |
| 2022 | Ownership or investment interest | 1 | $0 |
| 2021 | General payment | 164 | $90,781 |
| 2021 | Ownership or investment interest | 1 | $993 |
| 2020 | General payment | 87 | $59,956 |
| 2019 | General payment | 325 | $151,950 |
| 2019 | Research payment | 6 | $1,932 |
By company
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 260 | $741,127 |
| Consulting Fee | 70 | $109,843 |
| Travel and Lodging | 289 | $88,366 |
| Food and Beverage | 1,305 | $33,039 |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing | 8 | $26,900 |
| Honoraria | 3 | $12,360 |
| Compensation for serving as faculty or as a speaker for a medical education program | 6 | $7,475 |
| Research payment | 7 | $2,028 |
| Ownership or investment interest | 4 | $993 |
| Education | 6 | $300 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2025-12-30 | ABBVIE INC. | $11 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-12-24 | ABBVIE INC. | $28 | Food and Beverage | In-kind items and services | CREON Drug, ENDOCRINOLOGY | 2025 | |
| 2025-12-19 | ABBVIE INC. | $22 | Food and Beverage | In-kind items and services | LINZESS Drug, GASTROENTEROLOGY | 2025 | |
| 2025-12-18 | ABBVIE INC. | $1,600 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-12-18 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $24 | Food and Beverage | In-kind items and services | XIFAXAN Drug, Gastroenterology | 2025 | |
| 2025-12-18 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $16 | Food and Beverage | In-kind items and services | XIFAXAN Drug, Gastroenterology | 2025 | |
| 2025-12-16 | ABBVIE INC. | $23 | Food and Beverage | In-kind items and services | CREON Drug, ENDOCRINOLOGY | 2025 | |
| 2025-12-16 | Phathom Pharmaceuticals, Inc. | $10 | Food and Beverage | Cash or cash equivalent | VOQUEZNA Drug, Gastroenterology | 2025 | |
| 2025-12-15 | Madrigal Pharmaceuticals | $1,057 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-12-15 | GENZYME CORPORATION | $41 | Food and Beverage | In-kind items and services | DUPIXENT Biological, Immunology | 2025 | |
| 2025-12-12 | QOL Medical, LLC | $24 | Food and Beverage | In-kind items and services | Sucraid Drug, Genetic Disease | 2025 | |
| 2025-12-10 | Ipsen Biopharmaceuticals, Inc | $32 | Food and Beverage | In-kind items and services | IQIRVO Drug, Rare Disease | 2025 | |
| 2025-12-10 | PFIZER INC. | $26 | Food and Beverage | In-kind items and services | VELSIPITY Drug, INFLAMMATION;PAIN | 2025 | |
| 2025-12-09 | ABBVIE INC. | $18 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-12-09 | Phathom Pharmaceuticals, Inc. | $8 | Food and Beverage | Cash or cash equivalent | VOQUEZNA Drug, Gastroenterology | 2025 | |
| 2025-12-02 | Takeda Pharmaceuticals U.S.A., Inc. | $20 | Food and Beverage | In-kind items and services | HYQVIA Biological, IMMUNOLOGY | 2025 | |
| 2025-12-02 | ABBVIE INC. | $11 | Food and Beverage | In-kind items and services | MAVYRET Drug, VIROLOGY | 2025 | |
| 2025-12-02 | Janssen Biotech, Inc. | $7 | Food and Beverage | In-kind items and services | TREMFYA Drug, Immunology | 2025 | |
| 2025-12-01 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $86 | Food and Beverage | In-kind items and services | XIFAXAN Drug, Gastroenterology | 2025 | |
| 2025-11-25 | Ardelyx, Inc. | $24 | Food and Beverage | In-kind items and services | IBSRELA Drug, GASTROENTEROLOGY | 2025 | |
| 2025-11-25 | Madrigal Pharmaceuticals | $7 | Food and Beverage | In-kind items and services | REZDIFFRA Drug, LIVER DISEASE | 2025 | |
| 2025-11-24 | Janssen Biotech, Inc. | $10 | Food and Beverage | In-kind items and services | TREMFYA Drug, Immunology | 2025 | |
| 2025-11-20 | ABBVIE INC. | $2,400 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | VIBERZI Drug, GASTROENTEROLOGY | 2025 | |
| 2025-11-20 | PFIZER INC. | $23 | Food and Beverage | In-kind items and services | VELSIPITY Drug, INFLAMMATION;PAIN | 2025 | |
| 2025-11-20 | Alnylam Pharmaceuticals Inc. | $23 | Food and Beverage | In-kind items and services | ONPATTRO Drug, Genetic Disease | 2025 | |
| 2025-11-19 | ABBVIE INC. | $4,000 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | SKYRIZI Biological, IMMUNOLOGY | 2025 | |
| 2025-11-19 | GENZYME CORPORATION | $3,003 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | DUPIXENT Biological, Immunology | 2025 | |
| 2025-11-19 | ABBVIE INC. | $505 | Travel and Lodging | In-kind items and services | SKYRIZI Biological, IMMUNOLOGY | 2025 | |
| 2025-11-19 | ABBVIE INC. | $112 | Food and Beverage | In-kind items and services | SKYRIZI Biological, IMMUNOLOGY | 2025 | |
| 2025-11-18 | Janssen Biotech, Inc. | $19 | Food and Beverage | In-kind items and services | TREMFYA Drug, Immunology | 2025 | |
| 2025-11-18 | ABBVIE INC. | $11 | Food and Beverage | In-kind items and services | LINZESS Drug, GASTROENTEROLOGY | 2025 | |
| 2025-11-18 | PFIZER INC. | $9 | Food and Beverage | In-kind items and services | VELSIPITY Drug, INFLAMMATION;PAIN | 2025 | |
| 2025-11-17 | ABBVIE INC. | $5,600 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-11-17 | ABBVIE INC. | $27 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-11-17 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $23 | Food and Beverage | In-kind items and services | XIFAXAN Drug, Gastroenterology | 2025 | |
| 2025-11-15 | Gilead Sciences, Inc. | $21 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-11-13 | ABBVIE INC. | $4,000 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | SKYRIZI Biological, IMMUNOLOGY | 2025 | |
| 2025-11-11 | Janssen Biotech, Inc. | $22 | Food and Beverage | In-kind items and services | TREMFYA Drug, Immunology | 2025 | |
| 2025-11-04 | Janssen Biotech, Inc. | $10 | Food and Beverage | In-kind items and services | TREMFYA Drug, Immunology | 2025 | |
| 2025-10-30 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $24 | Food and Beverage | In-kind items and services | XIFAXAN Drug, Gastroenterology | 2025 | |
| 2025-10-30 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $1 | Food and Beverage | In-kind items and services | XIFAXAN Drug, Gastroenterology | 2025 | |
| 2025-10-29 | ABBVIE INC. | $585 | Travel and Lodging | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-10-29 | ABBVIE INC. | $106 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-10-29 | Phathom Pharmaceuticals, Inc. | $47 | Travel and Lodging | Cash or cash equivalent | VOQUEZNA Drug, Gastroenterology | 2025 | |
| 2025-10-29 | AngioDynamics, Inc. | $15 | Food and Beverage | In-kind items and services | ALPHAVAC Device, VIT | 2025 | |
| 2025-10-28 | Madrigal Pharmaceuticals | $3,878 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REZDIFFRA Drug, LIVER DISEASE | 2025 | |
| 2025-10-28 | Madrigal Pharmaceuticals | $148 | Food and Beverage | In-kind items and services | REZDIFFRA Drug, LIVER DISEASE | 2025 | |
| 2025-10-28 | ABBVIE INC. | $28 | Food and Beverage | In-kind items and services | VIBERZI Drug, GASTROENTEROLOGY | 2025 | |
| 2025-10-28 | Madrigal Pharmaceuticals | $13 | Travel and Lodging | Cash or cash equivalent | REZDIFFRA Drug, LIVER DISEASE | 2025 | |
| 2025-10-28 | Janssen Biotech, Inc. | $10 | Food and Beverage | In-kind items and services | TREMFYA Drug, Immunology | 2025 | |
| 2025-10-27 | ABBVIE INC. | $12 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-10-27 | Takeda Pharmaceuticals U.S.A., Inc. | $6 | Food and Beverage | In-kind items and services | ENTYVIO Biological, INTERNAL MEDICINE | 2025 | |
| 2025-10-25 | Janssen Biotech, Inc. | $1,400 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | STELARA Biological, Immunology | 2025 | |
| 2025-10-24 | Takeda Pharmaceuticals U.S.A., Inc. | $246 | Travel and Lodging | In-kind items and services | ENTYVIO Biological, INTERNAL MEDICINE | 2025 | |
| 2025-10-24 | Takeda Pharmaceuticals U.S.A., Inc. | $39 | Food and Beverage | In-kind items and services | ENTYVIO Biological, INTERNAL MEDICINE | 2025 | |
| 2025-10-24 | Janssen Biotech, Inc. | $31 | Food and Beverage | In-kind items and services | TREMFYA Drug, Immunology | 2025 | |
| 2025-10-24 | Takeda Pharmaceuticals U.S.A., Inc. | $6 | Travel and Lodging | In-kind items and services | ENTYVIO Biological, INTERNAL MEDICINE | 2025 | |
| 2025-10-23 | PFIZER INC. | $17 | Food and Beverage | In-kind items and services | ELIQUIS Drug, CARDIOVASCULAR;METABOLIC DISEASE | 2025 | |
| 2025-10-22 | ABBVIE INC. | $436 | Travel and Lodging | In-kind items and services | SKYRIZI Biological, IMMUNOLOGY | 2025 | |
| 2025-10-22 | ABBVIE INC. | $100 | Food and Beverage | In-kind items and services | SKYRIZI Biological, IMMUNOLOGY | 2025 | |
| 2025-10-21 | Takeda Pharmaceuticals U.S.A., Inc. | $6 | Food and Beverage | In-kind items and services | ENTYVIO Biological, INTERNAL MEDICINE | 2025 | |
| 2025-10-20 | ABBVIE INC. | $18 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-10-20 | ABBVIE INC. | $10 | Food and Beverage | In-kind items and services | SKYRIZI Biological, IMMUNOLOGY | 2025 | |
| 2025-10-16 | GENZYME CORPORATION | $33 | Food and Beverage | In-kind items and services | DUPIXENT Biological, Immunology | 2025 | |
| 2025-10-16 | Celltrion USA Inc. | $22 | Food and Beverage | In-kind items and services | VEGZELMA Biological, ONCOLOGY | 2025 | |
| 2025-10-15 | Janssen Biotech, Inc. | $22 | Food and Beverage | In-kind items and services | TREMFYA Drug, Immunology | 2025 | |
| 2025-10-15 | ABBVIE INC. | $7 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-10-14 | Takeda Pharmaceuticals U.S.A., Inc. | $5,729 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | ENTYVIO Biological, INTERNAL MEDICINE | 2025 | |
| 2025-10-14 | Boston Scientific Corporation | $25 | Food and Beverage | In-kind items and services | General - Therapies Device, General - Therapies_CRM | 2025 | |
| 2025-10-13 | Medtronic, Inc. | $68 | Food and Beverage | In-kind items and services | VITALFLOW CONSOLE Device, Cardiopulmonary | 2025 | |
| 2025-10-13 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $22 | Food and Beverage | In-kind items and services | XIFAXAN Drug, Gastroenterology | 2025 | |
| 2025-10-13 | ABBVIE INC. | $10 | Food and Beverage | In-kind items and services | MAVYRET Drug, VIROLOGY | 2025 | |
| 2025-10-10 | Janssen Biotech, Inc. | $36 | Food and Beverage | In-kind items and services | TREMFYA Drug, Immunology | 2025 | |
| 2025-10-08 | Phathom Pharmaceuticals, Inc. | $3,500 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | VOQUEZNA Drug, Gastroenterology | 2025 | |
| 2025-10-08 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $17 | Food and Beverage | In-kind items and services | XIFAXAN Drug, Gastroenterology | 2025 | |
| 2025-10-08 | Phathom Pharmaceuticals, Inc. | $11 | Food and Beverage | Cash or cash equivalent | VOQUEZNA Drug, Gastroenterology | 2025 | |
| 2025-10-07 | Janssen Biotech, Inc. | $25 | Food and Beverage | In-kind items and services | TREMFYA Drug, Immunology | 2025 | |
| 2025-10-06 | ABBVIE INC. | $18 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-10-06 | ABBVIE INC. | $13 | Food and Beverage | In-kind items and services | CREON Drug, ENDOCRINOLOGY | 2025 | |
| 2025-09-30 | Phathom Pharmaceuticals, Inc. | $115 | Food and Beverage | Cash or cash equivalent | VOQUEZNA Drug, Gastroenterology | 2025 | |
| 2025-09-30 | Janssen Biotech, Inc. | $29 | Food and Beverage | In-kind items and services | TREMFYA Drug, Immunology | 2025 | |
| 2025-09-30 | PFIZER INC. | $6 | Food and Beverage | In-kind items and services | XELJANZ Drug, GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | 2025 | |
| 2025-09-29 | ABBVIE INC. | $25 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-09-29 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $24 | Food and Beverage | In-kind items and services | XIFAXAN Drug, Gastroenterology | 2025 | |
| 2025-09-29 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $13 | Food and Beverage | In-kind items and services | XIFAXAN Drug, Gastroenterology | 2025 | |
| 2025-09-25 | Takeda Pharmaceuticals U.S.A., Inc. | $268 | Travel and Lodging | In-kind items and services | ENTYVIO Biological, INTERNAL MEDICINE | 2025 | |
| 2025-09-25 | Takeda Pharmaceuticals U.S.A., Inc. | $116 | Food and Beverage | In-kind items and services | ENTYVIO Biological, INTERNAL MEDICINE | 2025 | |
| 2025-09-25 | PFIZER INC. | $17 | Food and Beverage | In-kind items and services | ELIQUIS Drug, CARDIOVASCULAR;METABOLIC DISEASE | 2025 | |
| 2025-09-25 | Janssen Biotech, Inc. | $12 | Food and Beverage | In-kind items and services | TREMFYA Drug, Immunology | 2025 | |
| 2025-09-22 | Takeda Pharmaceuticals U.S.A., Inc. | $11 | Food and Beverage | In-kind items and services | ENTYVIO Biological, INTERNAL MEDICINE | 2025 | |
| 2025-09-20 | ABBVIE INC. | $24 | Food and Beverage | In-kind items and services | LINZESS Drug, GASTROENTEROLOGY | 2025 | |
| 2025-09-18 | GENZYME CORPORATION | $28 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-09-17 | Takeda Pharmaceuticals U.S.A., Inc. | $5,729 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | ENTYVIO Biological, INTERNAL MEDICINE | 2025 | |
| 2025-09-17 | ABBVIE INC. | $20 | Food and Beverage | In-kind items and services | CREON Drug, ENDOCRINOLOGY | 2025 | |
| 2025-09-16 | PFIZER INC. | $16 | Food and Beverage | In-kind items and services | VELSIPITY Drug, INFLAMMATION;PAIN | 2025 | |
| 2025-09-16 | Phathom Pharmaceuticals, Inc. | $7 | Food and Beverage | Cash or cash equivalent | VOQUEZNA Drug, Gastroenterology | 2025 | |
| 2025-09-15 | ABBVIE INC. | $11 | Food and Beverage | In-kind items and services | SKYRIZI Biological, IMMUNOLOGY | 2025 | |
| 2025-09-11 | Alnylam Pharmaceuticals Inc. | $17 | Food and Beverage | In-kind items and services | ONPATTRO Drug, Genetic Disease | 2025 | |
| 2025-09-09 | PFIZER INC. | $4 | Food and Beverage | In-kind items and services | VELSIPITY Drug, INFLAMMATION;PAIN | 2025 | |
| 2025-09-08 | ABBVIE INC. | $18 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-09-08 | Takeda Pharmaceuticals U.S.A., Inc. | $9 | Food and Beverage | In-kind items and services | ENTYVIO Biological, INTERNAL MEDICINE | 2025 | |
| 2025-09-08 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $6 | Food and Beverage | In-kind items and services | XIFAXAN Drug, Gastroenterology | 2025 | |
| 2025-09-05 | Lilly USA, LLC | $1,250 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | OMVOH Drug, Immunology | 2025 | |
| 2025-09-03 | Takeda Pharmaceuticals U.S.A., Inc. | $681 | Travel and Lodging | In-kind items and services | ENTYVIO Biological, INTERNAL MEDICINE | 2025 | |
| 2025-09-03 | Takeda Pharmaceuticals U.S.A., Inc. | $124 | Food and Beverage | In-kind items and services | ENTYVIO Biological, INTERNAL MEDICINE | 2025 | |
| 2025-09-03 | ABBVIE INC. | $21 | Food and Beverage | In-kind items and services | CREON Drug, ENDOCRINOLOGY | 2025 | |
| 2025-09-03 | Janssen Biotech, Inc. | $5 | Food and Beverage | In-kind items and services | TREMFYA Drug, Immunology | 2025 | |
| 2025-09-02 | Janssen Biotech, Inc. | $7 | Food and Beverage | In-kind items and services | TREMFYA Drug, Immunology | 2025 | |
| 2025-08-27 | ABBVIE INC. | $7 | Food and Beverage | In-kind items and services | MAVYRET Drug, VIROLOGY | 2025 | |
| 2025-08-26 | Lilly USA, LLC | $26 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-08-26 | ABBVIE INC. | $17 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-08-26 | PFIZER INC. | $6 | Food and Beverage | In-kind items and services | XELJANZ Drug, GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | 2025 | |
| 2025-08-25 | Takeda Pharmaceuticals U.S.A., Inc. | $7 | Food and Beverage | In-kind items and services | ENTYVIO Biological, INTERNAL MEDICINE | 2025 | |
| 2025-08-22 | Janssen Biotech, Inc. | $10 | Food and Beverage | In-kind items and services | TREMFYA Drug, Immunology | 2025 | |
| 2025-08-22 | Janssen Biotech, Inc. | $0 | Food and Beverage | In-kind items and services | TREMFYA Drug, Immunology | 2025 | |
| 2025-08-21 | Alnylam Pharmaceuticals Inc. | $27 | Food and Beverage | In-kind items and services | ONPATTRO Drug, Genetic Disease | 2025 | |
| 2025-08-19 | Eli Lilly and Company | $96 | Research payment | In-kind items and services | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, ACTIVE-CONTROLLED STUDY OF LY4268989 (MORF-057) CO-ADMINISTERED WITH | 2025 | |
| 2025-08-19 | Janssen Biotech, Inc. | $8 | Food and Beverage | In-kind items and services | TREMFYA Drug, Immunology | 2025 | |
| 2025-08-18 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $60 | Food and Beverage | In-kind items and services | XIFAXAN Drug, Gastroenterology | 2025 | |
| 2025-08-14 | Janssen Biotech, Inc. | $19 | Food and Beverage | In-kind items and services | TREMFYA Drug, Immunology | 2025 | |
| 2025-08-12 | Lilly USA, LLC | $28 | Food and Beverage | In-kind items and services | OMVOH Drug, Immunology | 2025 | |
| 2025-08-12 | Phathom Pharmaceuticals, Inc. | $8 | Food and Beverage | Cash or cash equivalent | VOQUEZNA Drug, Gastroenterology | 2025 | |
| 2025-08-11 | Madrigal Pharmaceuticals | $16 | Food and Beverage | In-kind items and services | REZDIFFRA Drug, LIVER DISEASE | 2025 | |
| 2025-08-11 | Takeda Pharmaceuticals U.S.A., Inc. | $10 | Food and Beverage | In-kind items and services | ENTYVIO Biological, INTERNAL MEDICINE | 2025 | |
| 2025-08-08 | PFIZER INC. | $375 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | VELSIPITY Drug, INFLAMMATION;PAIN | 2025 | |
| 2025-08-06 | Janssen Biotech, Inc. | $21 | Food and Beverage | In-kind items and services | TREMFYA Drug, Immunology | 2025 | |
| 2025-08-06 | PFIZER INC. | $17 | Food and Beverage | In-kind items and services | XELJANZ Drug, GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | 2025 | |
| 2025-08-05 | ABBVIE INC. | $8 | Food and Beverage | In-kind items and services | CREON Drug, ENDOCRINOLOGY | 2025 | |
| 2025-08-04 | ABBVIE INC. | $400 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-08-04 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $13 | Food and Beverage | In-kind items and services | XIFAXAN Drug, Gastroenterology | 2025 | |
| 2025-08-02 | Janssen Biotech, Inc. | $3,150 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | TREMFYA Drug, Immunology | 2025 | |
| 2025-07-31 | Madrigal Pharmaceuticals | $2,115 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REZDIFFRA Drug, LIVER DISEASE | 2025 | |
| 2025-07-30 | Ardelyx, Inc. | $15 | Food and Beverage | In-kind items and services | IBSRELA Drug, GASTROENTEROLOGY | 2025 | |
| 2025-07-29 | ABBVIE INC. | $400 | Consulting Fee | Cash or cash equivalent | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-07-29 | Phathom Pharmaceuticals, Inc. | $92 | Food and Beverage | Cash or cash equivalent | VOQUEZNA Drug, Gastroenterology | 2025 | |
| 2025-07-28 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $14 | Food and Beverage | In-kind items and services | XIFAXAN Drug, Gastroenterology | 2025 | |
| 2025-07-28 | Takeda Pharmaceuticals U.S.A., Inc. | $13 | Food and Beverage | In-kind items and services | ENTYVIO Biological, INTERNAL MEDICINE | 2025 | |
| 2025-07-26 | Janssen Biotech, Inc. | $507 | Travel and Lodging | In-kind items and services | TREMFYA Drug, Immunology | 2025 | |
| 2025-07-23 | ABBVIE INC. | $7 | Food and Beverage | In-kind items and services | LINZESS Drug, GASTROENTEROLOGY | 2025 | |
| 2025-07-22 | Lilly USA, LLC | $18 | Food and Beverage | In-kind items and services | OMVOH Drug, Immunology | 2025 | |
| 2025-07-22 | Janssen Biotech, Inc. | $10 | Food and Beverage | In-kind items and services | TREMFYA Drug, Immunology | 2025 | |
| 2025-07-22 | PFIZER INC. | $8 | Food and Beverage | In-kind items and services | VELSIPITY Drug, INFLAMMATION;PAIN | 2025 | |
| 2025-07-21 | ABBVIE INC. | $18 | Food and Beverage | In-kind items and services | SKYRIZI Biological, IMMUNOLOGY | 2025 | |
| 2025-07-21 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $12 | Food and Beverage | In-kind items and services | XIFAXAN Drug, Gastroenterology | 2025 | |
| 2025-07-21 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $8 | Food and Beverage | In-kind items and services | XIFAXAN Drug, Gastroenterology | 2025 | |
| 2025-07-19 | Janssen Biotech, Inc. | $875 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | STELARA Biological, Immunology | 2025 | |
| 2025-07-16 | ABBVIE INC. | $4,000 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | SKYRIZI Biological, IMMUNOLOGY | 2025 | |
| 2025-07-16 | Phathom Pharmaceuticals, Inc. | $12 | Food and Beverage | Cash or cash equivalent | VOQUEZNA Drug, Gastroenterology | 2025 | |
| 2025-07-15 | ABBVIE INC. | $14 | Food and Beverage | In-kind items and services | CREON Drug, ENDOCRINOLOGY | 2025 | |
| 2025-07-14 | Takeda Pharmaceuticals U.S.A., Inc. | $12 | Food and Beverage | In-kind items and services | ENTYVIO Biological, INTERNAL MEDICINE | 2025 | |
| 2025-07-10 | Aimmune Therapeutics, Inc. | $3,000 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | ZENPEP Drug, ENDOCRINE PANCREATIC INSUFFICIENCY | 2025 | |
| 2025-07-10 | Aimmune Therapeutics, Inc. | $52 | Travel and Lodging | In-kind items and services | ZENPEP Drug, ENDOCRINE PANCREATIC INSUFFICIENCY | 2025 | |
| 2025-07-09 | Aimmune Therapeutics, Inc. | $23 | Food and Beverage | In-kind items and services | ZENPEP Drug, ENDOCRINE PANCREATIC INSUFFICIENCY | 2025 | |
| 2025-07-08 | Lilly USA, LLC | $23 | Food and Beverage | In-kind items and services | OMVOH Drug, Immunology | 2025 | |
| 2025-07-08 | ABBVIE INC. | $8 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-07-07 | ABBVIE INC. | $7 | Food and Beverage | In-kind items and services | MAVYRET Drug, VIROLOGY | 2025 | |
| 2025-07-03 | PFIZER INC. | $7 | Food and Beverage | In-kind items and services | XELJANZ Drug, GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | 2025 | |
| 2025-07-02 | ABBVIE INC. | $21 | Food and Beverage | In-kind items and services | CREON Drug, ENDOCRINOLOGY | 2025 | |
| 2025-07-01 | Janssen Biotech, Inc. | $8 | Food and Beverage | In-kind items and services | TREMFYA Drug, Immunology | 2025 | |
| 2025-06-30 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $20 | Food and Beverage | In-kind items and services | XIFAXAN Drug, Gastroenterology | 2025 | |
| 2025-06-30 | Takeda Pharmaceuticals U.S.A., Inc. | $6 | Food and Beverage | In-kind items and services | ENTYVIO Biological, INTERNAL MEDICINE | 2025 | |
| 2025-06-28 | Madrigal Pharmaceuticals | $27 | Food and Beverage | In-kind items and services | REZDIFFRA Drug, LIVER DISEASE | 2025 | |
| 2025-06-26 | Aimmune Therapeutics, Inc. | $125 | Food and Beverage | In-kind items and services | ZENPEP Drug, ENDOCRINE PANCREATIC INSUFFICIENCY | 2025 | |
| 2025-06-26 | ABBVIE INC. | $18 | Food and Beverage | In-kind items and services | CREON Drug, ENDOCRINOLOGY | 2025 | |
| 2025-06-26 | PFIZER INC. | $14 | Food and Beverage | In-kind items and services | ELIQUIS Drug, CARDIOVASCULAR;METABOLIC DISEASE | 2025 | |
| 2025-06-24 | ABBVIE INC. | $4,000 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | LINZESS Drug, GASTROENTEROLOGY | 2025 | |
| 2025-06-23 | Lilly USA, LLC | $2,500 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | OMVOH Drug, Immunology | 2025 | |
| 2025-06-23 | Lilly USA, LLC | $1,575 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | OMVOH Drug, Immunology | 2025 | |
| 2025-06-20 | Takeda Pharmaceuticals U.S.A., Inc. | $17 | Food and Beverage | In-kind items and services | ENTYVIO Biological, INTERNAL MEDICINE | 2025 | |
| 2025-06-19 | Lilly USA, LLC | $744 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-06-18 | ABBVIE INC. | $120 | Food and Beverage | In-kind items and services | SKYRIZI Biological, IMMUNOLOGY | 2025 | |
| 2025-06-18 | ABBVIE INC. | $12 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-06-18 | PFIZER INC. | $8 | Food and Beverage | In-kind items and services | XELJANZ Drug, GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | 2025 | |
| 2025-06-17 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $99 | Food and Beverage | In-kind items and services | XIFAXAN Drug, Gastroenterology | 2025 | |
| 2025-06-16 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $20 | Food and Beverage | In-kind items and services | XIFAXAN Drug, Gastroenterology | 2025 | |
| 2025-06-13 | Lilly USA, LLC | $1,250 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | OMVOH Drug, Immunology | 2025 | |
| 2025-06-09 | Aimmune Therapeutics, Inc. | $192 | Travel and Lodging | In-kind items and services | ZENPEP Drug, ENDOCRINE PANCREATIC INSUFFICIENCY | 2025 | |
| 2025-06-09 | Aimmune Therapeutics, Inc. | $99 | Travel and Lodging | In-kind items and services | ZENPEP Drug, ENDOCRINE PANCREATIC INSUFFICIENCY | 2025 | |
| 2025-06-09 | Aimmune Therapeutics, Inc. | $58 | Food and Beverage | In-kind items and services | ZENPEP Drug, ENDOCRINE PANCREATIC INSUFFICIENCY | 2025 | |
| 2025-06-09 | Aimmune Therapeutics, Inc. | $52 | Travel and Lodging | In-kind items and services | ZENPEP Drug, ENDOCRINE PANCREATIC INSUFFICIENCY | 2025 | |
| 2025-06-09 | Aimmune Therapeutics, Inc. | $29 | Travel and Lodging | In-kind items and services | ZENPEP Drug, ENDOCRINE PANCREATIC INSUFFICIENCY | 2025 | |
| 2025-06-06 | Takeda Pharmaceuticals U.S.A., Inc. | $20 | Food and Beverage | In-kind items and services | EOHILIA Drug, INTERNAL MEDICINE | 2025 | |
| 2025-06-04 | AngioDynamics, Inc. | $31 | Food and Beverage | In-kind items and services | ALPHAVAC Device, VIT | 2025 | |
| 2025-06-04 | ABBVIE INC. | $2 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-06-03 | Takeda Pharmaceuticals U.S.A., Inc. | $19 | Food and Beverage | In-kind items and services | EOHILIA Drug, INTERNAL MEDICINE | 2025 | |
| 2025-06-03 | ABBVIE INC. | $9 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-05-30 | ABBVIE INC. | $8 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-05-29 | ABBVIE INC. | $110 | Food and Beverage | In-kind items and services | LINZESS Drug, GASTROENTEROLOGY | 2025 | |
| 2025-05-28 | Aimmune Therapeutics, Inc. | $2,812 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | ZENPEP Drug, ENDOCRINE PANCREATIC INSUFFICIENCY | 2025 | |
| 2025-05-28 | Celltrion USA Inc. | $20 | Food and Beverage | In-kind items and services | VEGZELMA Biological, ONCOLOGY | 2025 | |
| 2025-05-27 | PFIZER INC. | $68 | Food and Beverage | In-kind items and services | VELSIPITY Drug, INFLAMMATION;PAIN | 2025 | |
| 2025-05-22 | PFIZER INC. | $15 | Food and Beverage | In-kind items and services | ELIQUIS Drug, CARDIOVASCULAR;METABOLIC DISEASE | 2025 | |
| 2025-05-20 | ABBVIE INC. | $2,400 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | VIBERZI Drug, GASTROENTEROLOGY | 2025 | |
| 2025-05-20 | Phathom Pharmaceuticals, Inc. | $24 | Food and Beverage | Cash or cash equivalent | VOQUEZNA Drug, Gastroenterology | 2025 | |
| 2025-05-20 | Takeda Pharmaceuticals U.S.A., Inc. | $7 | Food and Beverage | In-kind items and services | ENTYVIO Biological, INTERNAL MEDICINE | 2025 | |
| 2025-05-19 | Lilly USA, LLC | $3,125 | Consulting Fee | Cash or cash equivalent | OMVOH Drug, Immunology | 2025 | |
| 2025-05-19 | Lilly USA, LLC | $2,200 | Consulting Fee | Cash or cash equivalent | OMVOH Drug, Immunology | 2025 | |
| 2025-05-19 | ABBVIE INC. | $7 | Food and Beverage | In-kind items and services | CREON Drug, ENDOCRINOLOGY | 2025 | |
| 2025-05-16 | ABBVIE INC. | $15 | Food and Beverage | In-kind items and services | MAVYRET Drug, VIROLOGY | 2025 | |
| 2025-05-14 | Phathom Pharmaceuticals, Inc. | $31 | Travel and Lodging | Cash or cash equivalent | VOQUEZNA Drug, Gastroenterology | 2025 |
The latest 200 records of 1,958.
Research payments naming this person as principal investigator
| Date | Company | Paid to | Amount | Study | Year |
|---|---|---|---|---|---|
| 2025-12-31 | ABBVIE INC. | TEXAS DIGESTIVE DISEASE CONS PLLC | $3,850 | A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Mod | 2025 |
| 2025-12-30 | ABBVIE INC. | TEXAS DIGESTIVE DISEASE CONS PLLC | $14,149 | A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Mod | 2025 |
| 2025-12-30 | ABBVIE INC. | TEXAS DIGESTIVE DISEASE CONS PLLC | $91,714 | A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Mod | 2025 |
| 2025-12-19 | Genentech, Inc. | TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC | $14,308 | Roche Cancer Screening Collection Study | 2025 |
| 2025-12-17 | Boehringer Ingelheim International GmbH | GI Alliance Of Illinois-Gurnee | $14 | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, an | 2025 |
| 2025-12-17 | Boehringer Ingelheim International GmbH | GI Alliance Of Illinois-Gurnee | $14 | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, an | 2025 |
| 2025-12-17 | Boehringer Ingelheim International GmbH | GI Alliance Of Illinois-Gurnee | $109 | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, an | 2025 |
| 2025-12-17 | Boehringer Ingelheim International GmbH | GI Alliance Of Illinois-Gurnee | $14 | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, an | 2025 |
| 2025-12-17 | Boehringer Ingelheim International GmbH | GI Alliance Of Illinois-Gurnee | $14 | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, an | 2025 |
| 2025-12-11 | Genentech, Inc. | TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC | $4,725 | A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants | 2025 |
| 2025-12-08 | Eli Lilly and Company | TEXAS DIGESTIVE DISEASE CONSULTANTS | $324 | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, ACTIVE-CONTROLLED STUDY OF LY4268989 (MORF-057) CO-ADMINISTERED WITH M | 2025 |
| 2025-12-04 | ABBVIE INC. | TEXAS DIGESTIVE DISEASE CONS PLLC | $3,081 | A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Mod | 2025 |
| 2025-12-01 | Phathom Pharmaceuticals, Inc. | TEXAS DIGESTIVE DISEASE CONSUL | $3,000 | EoE-201 | 2025 |
| 2025-12-01 | Phathom Pharmaceuticals, Inc. | TEXAS DIGESTIVE DISEASE CONSUL | $12,000 | EoE-201 | 2025 |
| 2025-11-21 | E.R. Squibb & Sons, L.L.C. | Texas Digestive Disease Consultants Southlake | $29,940 | A Phase 3, Multi-Center, Multi-National, Open-Label Extension Study to Evaluate the Long Term Efficacy and Safety of CC- | 2025 |
| 2025-11-13 | Boehringer Ingelheim International GmbH | GI Alliance Of Illinois-Gurnee | $2,195 | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, an | 2025 |
| 2025-11-13 | Boehringer Ingelheim International GmbH | GI Alliance Of Illinois-Gurnee | $2,195 | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, an | 2025 |
| 2025-11-13 | Boehringer Ingelheim International GmbH | GI Alliance Of Illinois-Gurnee | $154 | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, an | 2025 |
| 2025-11-13 | Boehringer Ingelheim International GmbH | GI Alliance Of Illinois-Gurnee | $11,410 | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, an | 2025 |
| 2025-10-27 | Boehringer Ingelheim International GmbH | GI Alliance Of Illinois-Gurnee | $474 | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, an | 2025 |
| 2025-10-27 | Boehringer Ingelheim International GmbH | GI Alliance Of Illinois-Gurnee | $23 | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, an | 2025 |
| 2025-10-27 | Boehringer Ingelheim International GmbH | GI Alliance Of Illinois-Gurnee | $39 | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, an | 2025 |
| 2025-10-27 | Boehringer Ingelheim International GmbH | GI Alliance Of Illinois-Gurnee | $9 | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, an | 2025 |
| 2025-10-27 | Boehringer Ingelheim International GmbH | GI Alliance Of Illinois-Gurnee | $9 | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, an | 2025 |
| 2025-10-27 | Boehringer Ingelheim International GmbH | GI Alliance Of Illinois-Gurnee | $9 | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, an | 2025 |
| 2025-10-27 | Boehringer Ingelheim International GmbH | GI Alliance Of Illinois-Gurnee | $9 | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, an | 2025 |
| 2025-10-09 | PFIZER INC. | TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC | $680 | AN OPENLABEL EXTENSION STUDY OF ETRASIMOD IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS | 2025 |
| 2025-10-09 | ABBVIE INC. | TEXAS DIGESTIVE DISEASE CONS PLLC | $2,696 | A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Mod | 2025 |
| 2025-09-24 | Genentech, Inc. | TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC | $392 | Roche Cancer Screening Collection Study | 2025 |
| 2025-09-24 | Genentech, Inc. | TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC | $867 | Roche Cancer Screening Collection Study | 2025 |
| 2025-09-18 | Genentech, Inc. | TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC | $3,390 | A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants | 2025 |
| 2025-09-04 | Ferring Pharmaceuticals AS | TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC | $1,908 | A Multi-center, Single-arm Trial Exploring the Safety and Clinical Effectiveness of RBX2660 Administered by Colonoscopy | 2025 |
| 2025-09-04 | ABBVIE INC. | TEXAS DIGESTIVE DISEASE CONS PLLC | $4,554 | A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Mod | 2025 |
| 2025-08-26 | Boehringer Ingelheim International GmbH | GI Alliance Of Illinois-Gurnee | $219 | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, an | 2025 |
| 2025-08-21 | Genentech, Inc. | TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC | $1,695 | A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants | 2025 |
| 2025-08-18 | GENZYME CORPORATION | Texas Digestive Disease Consultants Pllc Gi Alliance | $2,085 | A Phase 4, Randomized, Multicenter, Double-blind, Parallel-group, 24 Weeks, Placebo-controlled Study Followed by 104 Wee | 2025 |
| 2025-08-14 | Ferring Pharmaceuticals AS | TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC | $9,341 | A Multi-center, Single-arm Trial Exploring the Safety and Clinical Effectiveness of RBX2660 Administered by Colonoscopy | 2025 |
| 2025-08-06 | Takeda Pharmaceuticals U.S.A., Inc. | TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC | $668 | A PHASE 4 STUDY EVALUATING REAL-WORLD USE OF CDPATH?, A CROHN'S DISEASE RISK PREDICTION TOOL | 2025 |
| 2025-08-06 | Takeda Pharmaceuticals U.S.A., Inc. | TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC | $668 | A PHASE 4 STUDY EVALUATING REAL-WORLD USE OF CDPATH?, A CROHN'S DISEASE RISK PREDICTION TOOL | 2025 |
| 2025-08-06 | Takeda Pharmaceuticals U.S.A., Inc. | TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC | $668 | A PHASE 4 STUDY EVALUATING REAL-WORLD USE OF CDPATH?, A CROHN'S DISEASE RISK PREDICTION TOOL | 2025 |
| 2025-08-06 | ABBVIE INC. | TEXAS DIGESTIVE DISEASE CONS PLLC | $8,334 | A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Mod | 2025 |
| 2025-08-06 | Takeda Pharmaceuticals U.S.A., Inc. | TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC | $668 | A PHASE 4 STUDY EVALUATING REAL-WORLD USE OF CDPATH?, A CROHN'S DISEASE RISK PREDICTION TOOL | 2025 |
| 2025-08-06 | Takeda Pharmaceuticals U.S.A., Inc. | TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC | $668 | A PHASE 4 STUDY EVALUATING REAL-WORLD USE OF CDPATH?, A CROHN'S DISEASE RISK PREDICTION TOOL | 2025 |
| 2025-07-30 | Boehringer Ingelheim International GmbH | GI Alliance Of Illinois-Gurnee | $4,145 | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, an | 2025 |
| 2025-07-30 | Boehringer Ingelheim International GmbH | GI Alliance Of Illinois-Gurnee | $3,441 | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, an | 2025 |
| 2025-07-30 | Boehringer Ingelheim International GmbH | GI Alliance Of Illinois-Gurnee | $3,588 | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, an | 2025 |
| 2025-07-28 | Boehringer Ingelheim International GmbH | GI Alliance Of Illinois-Gurnee | $36 | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, an | 2025 |
| 2025-07-25 | Ferring Pharmaceuticals AS | TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC | $628 | A Multi-center, Single-arm Trial Exploring the Safety and Clinical Effectiveness of RBX2660 Administered by Colonoscopy | 2025 |
| 2025-07-22 | Genentech, Inc. | TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC | $160 | A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants | 2025 |
| 2025-07-21 | GENZYME CORPORATION | Texas Digestive Disease Consultants Pllc Gi Alliance | $1,050 | A Phase 4, Randomized, Multicenter, Double-blind, Parallel-group, 24 Weeks, Placebo-controlled Study Followed by 104 Wee | 2025 |
| 2025-07-14 | PFIZER INC. | TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC | $6,494 | AN OPENLABEL EXTENSION STUDY OF ETRASIMOD IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS | 2025 |
| 2025-07-11 | PFIZER INC. | TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC | $3,366 | AN OPENLABEL EXTENSION STUDY OF ETRASIMOD IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS | 2025 |
| 2025-07-02 | GENZYME CORPORATION | Texas Digestive Disease Consultants Pllc Gi Alliance | $194 | A Phase 4, Randomized, Multicenter, Double-blind, Parallel-group, 24 Weeks, Placebo-controlled Study Followed by 104 Wee | 2025 |
| 2025-07-02 | GENZYME CORPORATION | Texas Digestive Disease Consultants Pllc Gi Alliance | $45,381 | A Phase 4, Randomized, Multicenter, Double-blind, Parallel-group, 24 Weeks, Placebo-controlled Study Followed by 104 Wee | 2025 |
| 2025-07-02 | ABBVIE INC. | TEXAS DIGESTIVE DISEASE CONS PLLC | $10,007 | A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Mod | 2025 |
| 2025-07-01 | Boehringer Ingelheim International GmbH | GI Alliance Of Illinois-Gurnee | $55 | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, an | 2025 |
| 2025-06-24 | Boehringer Ingelheim International GmbH | GI Alliance Of Illinois-Gurnee | $328 | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, an | 2025 |
| 2025-06-24 | Ferring Pharmaceuticals AS | TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC | $37,849 | A Multi-center, Single-arm Trial Exploring the Safety and Clinical Effectiveness of RBX2660 Administered by Colonoscopy | 2025 |
| 2025-06-24 | Boehringer Ingelheim International GmbH | GI Alliance Of Illinois-Gurnee | $116 | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, an | 2025 |
| 2025-06-24 | Boehringer Ingelheim International GmbH | GI Alliance Of Illinois-Gurnee | $9 | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, an | 2025 |
| 2025-06-24 | Boehringer Ingelheim International GmbH | GI Alliance Of Illinois-Gurnee | $9 | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, an | 2025 |
| 2025-06-24 | Boehringer Ingelheim International GmbH | GI Alliance Of Illinois-Gurnee | $9 | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, an | 2025 |
| 2025-06-24 | Boehringer Ingelheim International GmbH | GI Alliance Of Illinois-Gurnee | $9 | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, an | 2025 |
| 2025-06-12 | ABBVIE INC. | TEXAS DIGESTIVE DISEASE CONS PLLC | $5,392 | A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Mod | 2025 |
| 2025-06-06 | Takeda Pharmaceuticals U.S.A., Inc. | TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC | $668 | A PHASE 4 STUDY EVALUATING REAL-WORLD USE OF CDPATH?, A CROHN'S DISEASE RISK PREDICTION TOOL | 2025 |
| 2025-06-01 | Boehringer Ingelheim International GmbH | GI Alliance Of Illinois-Gurnee | $55 | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, an | 2025 |
| 2025-05-27 | Genentech, Inc. | TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC | $2,922 | A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants | 2025 |
| 2025-05-15 | Ferring Pharmaceuticals AS | TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC | $533 | A Multi-center, Single-arm Trial Exploring the Safety and Clinical Effectiveness of RBX2660 Administered by Colonoscopy | 2025 |
| 2025-05-15 | ABBVIE INC. | TEXAS DIGESTIVE DISEASE CONS PLLC | $21,500 | A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treate | 2025 |
| 2025-05-08 | Boehringer Ingelheim International GmbH | GI Alliance Of Illinois-Gurnee | $1 | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, an | 2025 |
| 2025-05-08 | Boehringer Ingelheim International GmbH | GI Alliance Of Illinois-Gurnee | $147 | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, an | 2025 |
| 2025-05-08 | Boehringer Ingelheim International GmbH | GI Alliance Of Illinois-Gurnee | $147 | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, an | 2025 |
| 2025-05-08 | Genentech, Inc. | TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC | $3,447 | A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants | 2025 |
| 2025-05-08 | Boehringer Ingelheim International GmbH | GI Alliance Of Illinois-Gurnee | $30 | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, an | 2025 |
| 2025-05-07 | ABBVIE INC. | TEXAS DIGESTIVE DISEASE CONS PLLC | $6,463 | A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Mod | 2025 |
| 2025-05-01 | Boehringer Ingelheim International GmbH | GI Alliance Of Illinois-Gurnee | $55 | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, an | 2025 |
| 2025-04-30 | Genentech, Inc. | TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC | $976 | Roche Cancer Screening Collection Study | 2025 |
| 2025-04-24 | Boehringer Ingelheim International GmbH | GI Alliance Of Illinois-Gurnee | $20 | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, an | 2025 |
| 2025-04-24 | Boehringer Ingelheim International GmbH | GI Alliance Of Illinois-Gurnee | $25 | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, an | 2025 |
| 2025-04-23 | PFIZER INC. | TEXAS DIGESTIVE DISEASE CONSULTANTS | $74 | A MULTICENTER RANDOMIZED DOUBLEBLIND PARALLELGROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF ORAL ETRASIMOD AS INDUCTIO | 2025 |
| 2025-04-23 | Boehringer Ingelheim International GmbH | GI Alliance Of Illinois-Gurnee | $19 | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, an | 2025 |
| 2025-04-23 | Boehringer Ingelheim International GmbH | GI Alliance Of Illinois-Gurnee | $19 | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, an | 2025 |
| 2025-04-23 | Boehringer Ingelheim International GmbH | GI Alliance Of Illinois-Gurnee | $19 | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, an | 2025 |
| 2025-04-23 | Boehringer Ingelheim International GmbH | GI Alliance Of Illinois-Gurnee | $19 | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, an | 2025 |
| 2025-04-23 | Boehringer Ingelheim International GmbH | GI Alliance Of Illinois-Gurnee | $219 | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, an | 2025 |
| 2025-04-23 | PFIZER INC. | TEXAS DIGESTIVE DISEASE CONSULTANTS | $2,542 | A MULTICENTER RANDOMIZED DOUBLEBLIND PARALLELGROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF ORAL ETRASIMOD AS INDUCTIO | 2025 |
| 2025-04-23 | PFIZER INC. | TEXAS DIGESTIVE DISEASE CONSULTANTS | $1,906 | A MULTICENTER RANDOMIZED DOUBLEBLIND PARALLELGROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF ORAL ETRASIMOD AS INDUCTIO | 2025 |
| 2025-04-23 | PFIZER INC. | TEXAS DIGESTIVE DISEASE CONSULTANTS | $294 | A MULTICENTER RANDOMIZED DOUBLEBLIND PARALLELGROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF ORAL ETRASIMOD AS INDUCTIO | 2025 |
| 2025-04-23 | PFIZER INC. | TEXAS DIGESTIVE DISEASE CONSULTANTS | $1,358 | A MULTICENTER RANDOMIZED DOUBLEBLIND PARALLELGROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF ORAL ETRASIMOD AS INDUCTIO | 2025 |
| 2025-04-23 | PFIZER INC. | TEXAS DIGESTIVE DISEASE CONSULTANTS | $810 | A MULTICENTER RANDOMIZED DOUBLEBLIND PARALLELGROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF ORAL ETRASIMOD AS INDUCTIO | 2025 |
| 2025-04-09 | Takeda Pharmaceuticals U.S.A., Inc. | TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC | $668 | A PHASE 4 STUDY EVALUATING REAL-WORLD USE OF CDPATH?, A CROHN'S DISEASE RISK PREDICTION TOOL | 2025 |
| 2025-04-08 | Genentech, Inc. | TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC | $3,188 | A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants | 2025 |
| 2025-04-07 | Boehringer Ingelheim International GmbH | GI Alliance Of Illinois-Gurnee | $225 | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, an | 2025 |
| 2025-04-07 | Boehringer Ingelheim International GmbH | GI Alliance Of Illinois-Gurnee | $161 | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, an | 2025 |
| 2025-04-03 | ABBVIE INC. | TEXAS DIGESTIVE DISEASE CONS PLLC | $2,871 | A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Mod | 2025 |
| 2025-04-01 | Boehringer Ingelheim International GmbH | GI Alliance Of Illinois-Gurnee | $55 | Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, an | 2025 |
| 2025-04-01 | Genentech, Inc. | TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC | $3,400 | A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participan | 2025 |
| 2025-04-01 | Genentech, Inc. | TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC | $18,040 | A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participan | 2025 |
| 2025-03-28 | Genentech, Inc. | TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC | $976 | Roche Cancer Screening Collection Study | 2025 |
| 2025-03-25 | Genentech, Inc. | TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC | $7,695 | A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants | 2025 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Gurnee, IL, county Lake County, IL, state Illinois; placed by its city name.
| Measure | Place (city or town) Gurnee, IL | County Lake County, IL | State Illinois |
|---|---|---|---|
| Population B01003 | 30,510 | 714,223 | 12,694,798 |
| Population, 2020 census P1 | 30,706 | 714,342 | 12,812,508 |
| Median age B01002 | 40.1 | 39.1 | 39.0 |
| Under 18 B01001 | 20.3% | 23.3% | 21.8% |
| 65 and over B01001 | 15.5% | 15.8% | 17.0% |
| Households B11001 | 11,779 | 258,455 | 5,036,449 |
| Foreign born B05002 | 17.0% | 19.8% | 14.7% |
| Median household income B19013 | $119,628 | $110,416 | $83,390 |
| Median family income B19113 | $158,467 | $135,361 | $106,018 |
| Per capita income B19301 | $58,525 | $57,153 | $46,406 |
| Poverty rate B17001 | 5.2% | 8.3% | 11.8% |
| Unemployment rate B23025 | 4.8% | 5.2% | 5.8% |
| Civilian labor force B23025 | 17,286 | 376,923 | 6,652,134 |
| Mean commute (minutes) B08013 | 27.4 | 28.5 | 27.8 |
| Bachelor's degree or higher B15003 | 56.7% | 47.7% | 37.8% |
| Housing units B25001 | 12,081 | 270,618 | 5,457,452 |
| Owner-occupied B25003 | 76.1% | 74.8% | 67.1% |
| Renters B25003 | 23.9% | 25.2% | 32.9% |
| Median home value B25077 | $344,300 | $345,700 | $263,300 |
| Median gross rent B25064 | $1,655 | $1,477 | $1,274 |
| White, not Hispanic B03002 | 58.2% | 56.2% | 58.1% |
| Black B03002 | 7.7% | 6.3% | 13.3% |
| Hispanic or Latino B03002 | 17.0% | 24.9% | 18.8% |
| Asian B03002 | 12.9% | 8.6% | 5.9% |
| American Indian and Alaska Native B03002 | 0.1% | 0.1% | 0.1% |
Economy now FRED unemployment 4.6% in Sep 2026 (4.5% a year earlier); per capita personal income $78,987 in 2025, up 28% in five years (+3.1% after inflation); the state; Source: FRED, Federal Reserve Bank of St. Louis.
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Gurnee, IL.
Comments